Appendix 4C - Quarterly Cashflow Report
Starpharma today released its Appendix 4C – Quarterly Cashflow report for the period ended 30 September 2013.
The cash balance at 30 September 2013 was $31.5 million, a net cash burn of $2.3 million for the quarter.
Starpharma's Dendrimer-Docetaxel eliminates neutropenia
Starpharma today announced additional positive results for its dendrimer formulation of the major chemotherapeutic, docetaxel (Taxotere®), ahead of its advancement into clinical trials later this year.
The Business on ABC TV: Interview with Starpharma CEO Jackie Fairley
ABC News’ The Business Presenter Ticky Fullerton interviewed Starpharma CEO Dr Jackie Fairley on Wednesday 16th October 2013. Ticky discussed the positive results of Starpharma’s dendrimer version of oxaliplatin.
Sky Business News: Interview with Starpharma CEO Jackie Fairley
Starpharma CEO Dr Jackie Fairley joined Sky News to discuss the positive results of the Company’s pre-clinical trial of Dendrimer-Enhanced Oxaliplatin. Starpharma’s dendrimer version of the blockbuster colon and colorectal cancer drug was shown to be less neurotoxic than conventional oxaliplatin.
Reduced neurotoxicity with SPL's dendrimer enhanced oxaliplatin
Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced further positive results for its Dendrimer-Enhanced Oxaliplatin (DEO), specifically that its dendrimer version of oxaliplatin results in a significant reduction in the serious neurotoxicity commonly seen with oxaliplatin.